Thursday, January 24, 2013

KEEPING YOU IN THE LOOP...Recent Clinical Trial Update


Bristol-Myers Squibb Company and Pfizer, Inc., announced the U.S. Food and Drug Administration (FDA) approved Eliqius® (apixaban), a medicine used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation in the United States, Canada, European Union and Japan.

Eliquis is new treatment option for reducing the risk of stroke.

Thank you and congratulations to the volunteers, PMG Sites and Investigators who contributed to the development of this new medication for stroke prevention through their participation in this clinical research study.

Be sure to
click here to read the US Approved Press Release.

No comments :

Post a Comment

Subscribe Via Email